Table 4 Relationship betweenEZH2 expression in primary and metastatic breast cancer lesions and the clinicopathological characteristics of patients (n = 96)
Characteristic | Primary EZH2 | P-value | Metastatic EZH2 | P-value | ||
|---|---|---|---|---|---|---|
low (n = 42) | high (n = 54) | low (n = 17) | high (n = 79) | |||
Age, years (mean ± SD) | 52 ± 8.5 | 50 ± 9.8 | 0.198 | 50 ± 7.8 | 51 ± 9.7 | 0.241 |
Menopausal status, n (%) | ||||||
 pre- | 17 (38.6) | 27 (61.4) | 0.353 | 10 (22.7) | 34 (77.3) | 0.236 |
 post- | 25 (48.1) | 27 (51.9) |  | 7 (13.5) | 45 (86.5) |  |
Tumor size, n (%) | ||||||
  ≤ 20 mm | 8 (47.1) | 9 (52.9) |  | 2 (11.8) | 15 (88.2) |  |
  > 20 mm | 33 (42.9) | 44 (57.1) | 0.936 | 14 (18.2) | 63 (81.8) | 0.396 |
 unknown | 1 (50.0) | 1 (50.0) |  | 1 (50.0) | 1 (50.0) |  |
LN status, n (%) | ||||||
 positive | 23 (36.5) | 40 (63.5) |  | 11 (17.5) | 52 (82.5) |  |
 negative | 19 (57.6) | 14 (42.4) | 0.048* | 6 (18.2) | 27 (81.8) | 0.930 |
Histological type, n (%) | ||||||
 ductal | 32 (38.6) | 51 (61.4) | 0.010* | 12 (14.5) | 71 (85.5) | 0.035* |
 special | 10 (76.9) | 3 (23.1) |  | 5 (38.5) | 8 (61.5) |  |
LVI status, n (%) | ||||||
 positive | 32 (50.8) | 31 (49.2) |  | 11 (17.5) | 52 (82.5) |  |
 negative | 8 (32.0) | 17 (68.0) | 0.148 | 4 (16.0) | 21 (84.0) | 0.842 |
 unknown | 2 (25.0) | 6 (75.0) |  | 2 (25.0) | 6 (75.0) |  |
Operation status, n (%) | ||||||
 partial mastectomy | 4 (23.5) | 13 (76.5) | 0.064 | 2 (11.8) | 15 (88.2) | 0.479 |
 mastectomy | 38 (48.1) | 41 (51.9) |  | 15 (19.0) | 64 (81.0) |  |
Chemotherapy, n (%) | ||||||
 adjuvant | 34 (41.0) | 49 (59.0) | 0.164 | 12 (14.5) | 71 (85.5) | 0.035* |
 none | 8 (61.5) | 5 (38.5) |  | 5 (38.5) | 8 (61.5) |  |
Hormone therapy, n (%) | ||||||
 adjuvant | 26 (52.0) | 24 (48.0) | 0.089 | 12 (24.0) | 38 (76.0) | 0.092 |
 none | 16 (34.8) | 30 (65.2) |  | 5 (10.9) | 41 (89.1) |  |
Primary ER status, n (%) | ||||||
 positive | 28 | 23 | 0.019* | 12 | 39 | 0.112 |
 negative | 14 | 31 |  | 5 | 40 |  |
Primary PR status, n (%) | ||||||
 positive | 24 | 23 | 0.157 | 12 | 35 | 0.049* |
 negative | 18 | 31 |  | 5 | 44 |  |
Primary HER2 status, n (%) | ||||||
 positive | 1 | 15 | 0.001* | 0 | 16 | 0.042* |
 negative | 41 | 39 |  | 17 | 63 |  |
Primary Ki-67 expression, n (%) | ||||||
 high | 8 | 47 | <0.001* | 2 | 53 | <0.001* |
 low | 34 | 7 |  | 15 | 26 |  |
Metastatic ER status, n (%) | ||||||
 positive | 21 | 20 | 0.203 | 8 | 33 | 0.689 |
 negative | 21 | 34 |  | 9 | 46 |  |
Metastatic PR status, n (%) | ||||||
 positive | 22 | 17 | 0.039* | 9 | 30 | 0.254 |
 negative | 20 | 37 |  | 8 | 49 |  |
Metastatic HER2 status, n (%) | ||||||
 positive | 1 | 13 | 0.003* | 0 | 14 | 0.060 |
 negative | 41 | 41 |  | 17 | 65 |  |
Metastatic Ki-67 expression, n (%) | ||||||
 high | 23 | 49 | <0.001* | 2 | 70 | <0.001* |
 low | 19 | 5 |  | 15 | 9 |  |
Site of recurrence, n (%) | ||||||
 viscerab | 14 (37.8) | 23 (62.2) | 0.102 | 5 (13.5) | 32 (86.5) | 0.012* |
 soft tissuec | 13 (37.1) | 22 (62.9) |  | 3 (8.6) | 32 (91.4) |  |
 bone | 15 (62.5) | 9 (37.5) |  | 9 (37.5) | 15 (62.5) |  |
Disease free interval | ||||||
  ≤ 2 years | 7 (23.5) | 24(77.4) | 0.04* | 4 (12.9) | 27 (87.1) | 0.394 |
  > 2 years | 35 (53.8) | 30 (46.1) |  | 13 (20) | 52 (80) |  |
  ≤ 10 years | 32 (38.6) | 51 (61.4) | 0.010* | 13 (15.7) | 70 (84.3) | 0.185 |
  > 10 years | 10 (76.9) | 3 (23.1) |  | 4 (30.8) | 9 (69.2) |  |